Mural Oncology (NASDAQ:MURA – Get Free Report) released its earnings results on Tuesday. The company reported ($2.01) earnings per share for the quarter, missing the consensus estimate of ($1.96) by ($0.05), RTT News reports.
Mural Oncology Price Performance
MURA stock traded up $0.17 during midday trading on Tuesday, reaching $3.80. 146,728 shares of the company were exchanged, compared to its average volume of 162,217. Mural Oncology has a one year low of $2.87 and a one year high of $5.46. The firm has a market capitalization of $64.68 million, a price-to-earnings ratio of -0.42 and a beta of 3.66. The business has a 50-day moving average price of $3.83 and a two-hundred day moving average price of $3.58.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Mural Oncology in a research report on Monday, November 11th.
Mural Oncology Company Profile
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Read More
- Five stocks we like better than Mural Oncology
- Airline Stocks – Top Airline Stocks to Buy Now
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- How to trade penny stocks: A step-by-step guide
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Mural Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mural Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
